Blood Advances · 2019 · 15 citations · 39 references
Patient SelectionEligibility CriteriaClinical EndpointAplastic AnemiaMyeloid NeoplasiaHematological MalignancyBone Marrow FailureT-mds Patient ExclusionClinical PopulationHematologyClinical TrialsRandomized Controlled TrialTherapy-related Myelodysplastic SyndromeRadiation OncologyHealth SciencesHealth PolicyKey Points PatientsOutcomes ResearchMalignant Blood DisorderPast 20Medicine
Key Points Patients with t-MDS are underrepresented in clinical trials when taking into account the prevalence of such patients. Eligibility criteria and sponsorship type may contribute to t-MDS patient exclusion.
39
Michael Lübbert, Stefan Suciu, Liliana Baila et al. · Journal of Clinical Oncology · 2011 · 546 citations · Full text
Thomas Fischer, Richard M. Stone, Daniel J. DeAngelo et al. · Journal of Clinical Oncology · 2010 · 501 citations · Full text